Clinical Trials Logo

Clinical Trial Summary

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-2002 injection monotherapy and in combination with other anti-cancer therapy for advanced malignant tumors of patients. To explore the reasonable dosage of SHR-2002 injection monotherapy and dosage regimen of combination therapy for advanced malignant tumors of patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05198817
Study type Interventional
Source Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Contact
Status Enrolling by invitation
Phase Phase 1
Start date February 22, 2022
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04980690 - Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05082545 - Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT04128085 - A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors Phase 1
Recruiting NCT05229497 - A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors Phase 1/Phase 2
Not yet recruiting NCT05235542 - A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05354076 - Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo Phase 2
Not yet recruiting NCT05396391 - A Phase I/IIa Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05110807 - A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05214482 - A Study of AK112 in Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05223231 - Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05193721 - A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors Phase 1
Recruiting NCT04708210 - Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors Phase 1